However, despite these constraints, the study provides preliminary results that may support the increasing recognition of PCSK9 inhibitors and inclisiran as a novel and efficacious treatment option for patients with familial hypercholesterolemia or those at very high risk of cardiovascular diseases. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.